Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 6/20 | 0.41 |
| ▸ | PDE4A | P27815 | 6/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18557126 | 1.00 | CHRM3 (0.41) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18557111 | 1.00 | CHRM3 (0.41) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18557124 | 1.00 | CHRM3 (0.41) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL26984682 | 0.98 | CHRM3 (0.38) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1286191 | 0.88 | CHRM3 (0.41) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21573272 | 0.86 | GSK3A (0.40) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17376493 | 0.86 | CHRM3 (0.40) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16682874 | 0.84 | GSK3A (0.39) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15103644 | 0.84 | BACE1 (0.37) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15103604 | 0.79 | BACE1 (0.33) | CHRM3PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256703-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2014-09-11 | — | — | US | disclosed |
| US-20140256703-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2014-09-11 | — | — | US | disclosed |
| US-20140256703-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2014-09-11 | — | — | US | disclosed |
| US-8426425-B2 | Aminopyrimidines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426425-B2 | Aminopyrimidines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426425-B2 | Aminopyrimidines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2099787-B1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2010-07-21 | — | — | EP | disclosed |
| EP-2099787-B1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2010-07-21 | — | — | EP | disclosed |
| US-20100022507-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022507-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022507-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-28 | — | — | US | disclosed |
| WO-2008077086-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022507-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K5, MAP3K20, PRKDC | CHRM3 4852/4885PDE4A 827/4885PDE4B 890/4885 |
| US-20140256703-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K5, MAP3K20, PRKDC | CHRM3 4852/4885PDE4A 827/4885PDE4B 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.